Two active pharmaceutical ingredients under CHINARES PHARMA passed the drug GMP compliance inspection

AASTOCKS
2025.09.03 04:16

CHINARES PHARMA (03320.HK) announced that its subsidiary Zhejiang Xinsai Ke Pharmaceutical Co., Ltd. has received the "Drug GMP Compliance Inspection Notification" issued by the Zhejiang Provincial Drug Administration for fenofibrate raw material and azilsartan raw material.

Fenofibrate raw material is used to lower triglyceride levels in patients with severe hypertriglyceridemia and for the treatment of primary hypercholesterolemia or mixed dyslipidemia, while azilsartan raw material is used for the treatment of hypertension.

This drug GMP compliance inspection is the first GMP compliance inspection for fenofibrate raw material and azilsartan raw material before their market launch, indicating that the group's product quality control meets GMP requirements

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.